info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)
Certified Global Research Member
Isomar 1 Iso 1
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

GLP 1 Analogue Market Research Report By Formulation (Injectable, Oral, Nasal, Transdermal), By Dosage Strength (1 mg, 1-5 mg, 5 mg), By Target Population (Type 1 Diabetes, Type 2 Diabetes), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2034


ID: MRFR/HC/27882-HCR | 128 Pages | Author: Kinjoll Dey| August 2025

GLP 1 Analogue Market Overview

As per MRFR analysis, the GLP 1 Analogue Market Size was estimated at 26.34 (USD Billion) in 2024. The GLP 1 Analogue Market Industry is expected to grow from 29.27 (USD Billion) in 2025 to 75.62 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 11.12% during the forecast period (2025 - 2034).

Key GLP 1 Analogue Market Trends Highlighted

Emerging therapies in the GLP-1 analog market are targeting underpenetrated patient populations and unmet clinical needs. Novel GLP-1 analogs are being developed to address the limitations of existing treatments, such as reduced efficacy in advanced disease stages or the need for frequent injections. These new therapies aim to provide improved patient outcomes and enhance the competitive landscape.

Strategic partnerships and collaborations are prevalent in the GLP-1 analog market, fostering innovation and leveraging expertise. Pharmaceutical companies are forming alliances to expand their product portfolios, gain access to new technologies, and accelerate the development and commercialization of novel GLP-1 analogs. These collaborations aim to address unmet medical needs and enhance the overall market dynamics.

Artificial intelligence (AI) and machine learning (ML) are gaining prominence in the GLP-1 analog market. AI-powered tools assist in drug discovery services, clinical trial design, and patient stratification, enabling more efficient and personalized treatment approaches.

ML algorithms analyze vast amounts of data to identify patterns and predict patient responses, contributing to improved clinical decision-making and optimized patient management. AI and ML are transforming the market by enhancing the development and delivery of GLP-1 analog therapies.

GLP 1 Analogue Market Overview

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Increasing Prevalence of Diabetes

Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels. GLP-1 analogs are a class of drugs used to treat type 2 diabetes by mimicking the effects of the natural hormone GLP-1, which stimulates insulin secretion and inhibits glucagon secretion.

The rising prevalence of diabetes globally is a major driver of the GLP-1 analog market. According to the International Diabetes Federation, the number of people with diabetes worldwide is expected to reach 643 million by 2030.

This growing patient population is fueling the demand for effective diabetes treatments, including GLP-1 analogs.

Technological Advancements and New Product Launches

The GLP-1 analog market is witnessing significant technological advancements and new product launches. Pharmaceutical companies are continuously investing in research and development to improve the efficacy, safety, and convenience of GLP-1 analogs. For instance, in 2023, Novo Nordisk launched a new once-weekly GLP-1 analog called Wegovy, which has shown promising results in clinical trials. These advancements are expanding the treatment options for patients with diabetes and driving the growth of the global GLP-1 analog market.

Government Initiatives and Reimbursement Policies

Government initiatives and reimbursement policies play a crucial role in shaping the GLP-1 analog market. Many governments are implementing programs to improve access to diabetes care and reduce healthcare costs.

For example, the US Medicare program covers GLP-1 analogs for patients with type 2 diabetes who meet certain criteria. These favorable policies are encouraging the adoption of GLP-1 analogs and contributing to the growth of the global GLP-1 analog market.

GLP 1 Analogue Market Segment Insights

GLP 1 Analogue Market Formulation Insights

The GLP 1 Analogue Market segmentation by Formulation comprises Injectable, Oral, Nasal, and Transdermal formulations. Injectable formulation dominated the market in 2023 and is projected to maintain its dominance throughout the forecast period.

The dominance of injectable GLP-1 analogs can be attributed to their high efficacy, rapid onset of action, and ability to provide sustained drug delivery. However, the increasing prevalence of diabetes and obesity is expected to drive the growth of the oral GLP-1 analog segment during the forecast period.

The oral GLP-1 analog segment is projected to witness significant growth over the forecast period due to the convenience and ease of administration associated with oral formulations.

Moreover, the development of new, longer-acting oral GLP-1 analogs is expected to further fuel the growth of this segment. The nasal and transdermal segments are expected to experience moderate growth over the forecast period, owing to their non-invasive nature and potential for improved patient compliance.

In 2023, the GLP 1 Analogue Market for Injectable formulations was valued at around USD 12.5 billion and is projected to reach USD 27.8 billion by 2032, exhibiting a CAGR of 10.1% during the forecast period.

The Oral formulation segment is projected to grow from USD 6.3 billion in 2023 to USD 18.7 billion by 2032, at a CAGR of 12.5%. The Nasal and Transdermal segments are expected to grow at CAGRs of 9.2% and 8.5%, respectively, over the forecast period.

The growth of the Global GLP-1 Analogue Market is attributed to the rising prevalence of diabetes and obesity, increasing awareness about the benefits of GLP-1 analogs, and the introduction of new and innovative products.

The market is expected to witness further growth in the coming years due to the increasing adoption of GLP-1 analogs in the treatment of diabetes and obesity, expanding healthcare infrastructure in emerging markets, and supportive government policies.

GLP 1 Analogue Market 2 

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

GLP 1 Analogue Market Dosage Strength Insights

The GLP 1 Analogue Market segmentation by Dosage Strength is expected to grow at a CAGR of 10.1% during the forecast period from 2025 to 2034. The market is segmented into three categories: '1 mg', '1-5 mg', and '5 mg'.

Among these, the '1-5 mg' segment is expected to hold the largest share of the market by 2032, with a valuation of USD 25.48 billion. This growth can be attributed to the increasing prevalence of type 2 diabetes and the rising demand for effective and convenient treatment options.

The '1 mg' segment is also expected to witness significant growth due to the launch of new products and the growing adoption of personalized medicine.

GLP 1 Analogue Market Target Population Insights

The target population for the GLP 1 Analogue Market is segmented into Type 1 Diabetes and Type 2 Diabetes. Type 1 Diabetes is an autoimmune disease in which the pancreas produces little or no insulin, a hormone that regulates blood sugar levels. Type 2 Diabetes is a chronic condition in which the body becomes resistant to insulin or does not produce enough insulin.

In 2023, the GLP 1 Analogue Market revenue for Type 1 Diabetes was around USD 12.5 billion, and it is projected to reach USD 21.5 billion by 2032, exhibiting a CAGR of 6.5%.

The increasing prevalence of Type 1 Diabetes, coupled with the rising adoption of GLP-1 analogs for its effective blood glucose control, is driving the growth of this segment. Type 2 Diabetes is the most common type of diabetes, accounting for over 90% of all cases.

The GLP 1 Analogue Market revenue for Type 2 Diabetes was around USD 9.8 billion in 2023, and it is projected to reach USD 28.5 billion by 2032, exhibiting a CAGR of 12.4%. The growing prevalence of Type 2 Diabetes, advancements in GLP-1 analog formulations, and increasing awareness about the benefits of GLP-1 analogs are contributing to the growth of this segment.

GLP 1 Analogue Market Distribution Channel Insights

The distribution channel segment plays a crucial role in the growth of the GLP 1 Analogue Market. Hospitals account for a significant share of the market, owing to the high volume of GLP-1 analog prescriptions and administration in hospital settings.

In 2023, the hospital segment contributed over 50% of the GLP 1 Analogue Market revenue. Retail pharmacies are also a key distribution channel, particularly for patients with chronic conditions who require ongoing GLP-1 analog therapy. The convenience and accessibility of retail pharmacies drive their growth in this segment.

Online pharmacies are gaining traction as a distribution channel, offering convenience and competitive pricing. The GLP 1 Analogue Market is expected to witness a surge in online pharmacy sales, driven by the increasing adoption of e-commerce for healthcare products and services.

GLP 1 Analogue Market Regional Insights

The GLP 1 Analogue Market regional segmentation provides insights into the market's geographic performance. The regions considered in this report are North America, Europe, APAC, South America, and MEA.

Among these regions, North America is expected to hold the largest market share throughout the forecast period due to the high prevalence of diabetes and the increasing adoption of GLP 1 Analogues for the treatment of type 2 diabetes. Europe is another significant region in the GLP 1 Analogue Market, driven by the rising prevalence of diabetes and government initiatives to improve healthcare infrastructure.

The APAC region is projected to witness substantial growth in the coming years due to the increasing awareness of diabetes and the growing disposable income of the population. South America and MEA are emerging markets with a growing demand for GLP 1 Analogues as diabetes rates continue to rise in these regions.

GLP 1 Analogue Market 3 

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

GLP 1 Analogue Market Key Players and Competitive Insights

Major players in the GLP 1 Analogue Market are continuously investing in research and development to enhance their product portfolios. They are also focusing on strategic collaborations and partnerships to expand their global reach. The GLP 1 Analogue Market is characterized by intense competition, with leading players constantly vying for market share.

Some of the key competitive strategies adopted by these players include product differentiation, innovation, and aggressive marketing campaigns. The GLP-1 Analogue Market development is driven by factors such as the rising prevalence of diabetes, increasing awareness about the benefits of GLP-1 analogs, and favorable reimbursement policies. The GLP 1 Analogue Market Competitive Landscape is expected to remain highly competitive in the coming years, with new entrants and established players alike looking to gain a foothold in this lucrative market.

Novo Nordisk, a leading GLP 1 Analogue Market player, has a strong global presence and a diverse portfolio of GLP-1 analogues. The company's flagship product, Victoza, is widely used for the treatment of type 2 diabetes. Novo Nordisk is known for its commitment to innovation and its focus on developing novel GLP-1 analogs with improved efficacy and safety profiles.

Eli Lilly, another major player in the GLP-1 Analogue Market, has a strong pipeline of GLP-1 analogs in development. The company's Trulicity product has shown promising results in clinical trials and is expected to be a major growth driver in the coming years. Eli Lilly is also actively involved in the research and development of next-generation GLP-1 analogs that offer longer-lasting effects and fewer side effects.

Key Companies in the GLP 1 Analogue Market Include

  • Emisphere Technologies
  • Intarcia Therapeutics
  • Lexicon Pharmaceuticals
  • AstraZeneca
  • PhaseBio Pharmaceuticals
  • Incretins
  • Xeris Pharmaceuticals
  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk
  • Merck Co., Inc.
  • Zosano Pharma
  • Zealand Pharma
  • Boehringer Ingelheim
  • Rhythm Pharmaceuticals

GLP 1 Analogue Market Developments

  • Q2 2024: Novo Nordisk to invest $4.1 billion in new U.S. manufacturing facility to boost GLP-1 drug output Novo Nordisk announced a $4.1 billion investment to build a new manufacturing facility in North Carolina, aiming to increase production capacity for its GLP-1-based diabetes and obesity drugs amid surging demand.
  • Q2 2024: Eli Lilly to acquire manufacturing site in Germany to expand GLP-1 drug production Eli Lilly disclosed the acquisition of a new manufacturing site in Alzey, Germany, to scale up production of its GLP-1 analogue medications, responding to global shortages and rising demand.
  • Q2 2024: Novo Nordisk receives FDA approval for Wegovy (semaglutide) for cardiovascular risk reduction in adults with obesity The FDA approved an expanded indication for Novo Nordisk’s GLP-1 analogue Wegovy, allowing its use to reduce the risk of major cardiovascular events in adults with obesity and established cardiovascular disease.
  • Q2 2024: AstraZeneca and Eccogene announce partnership to develop next-generation oral GLP-1 agonists AstraZeneca entered a strategic partnership with Eccogene to co-develop and commercialize novel oral GLP-1 receptor agonists for type 2 diabetes and obesity, with upfront and milestone payments disclosed.
  • Q3 2024: Eli Lilly receives European Commission approval for Zepbound (tirzepatide) for chronic weight management The European Commission granted marketing authorization to Eli Lilly’s Zepbound, a GLP-1/GIP dual agonist, for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity.
  • Q3 2024: Novo Nordisk to acquire Cardior Pharmaceuticals for up to €1.025 billion to expand cardiometabolic pipeline Novo Nordisk announced the acquisition of Cardior Pharmaceuticals, a German biotech focused on RNA-based therapies for heart disease, to strengthen its cardiometabolic portfolio, including GLP-1-based treatments.
  • Q3 2024: Sanofi announces $1.5 billion investment in new French facility for GLP-1 drug production Sanofi revealed plans to invest $1.5 billion in a new manufacturing facility in France dedicated to the production of GLP-1 analogues, aiming to meet growing European demand.
  • Q4 2024: Novo Nordisk and Flagship Pioneering launch partnership to develop novel GLP-1-based therapeutics Novo Nordisk and Flagship Pioneering announced a multi-year partnership to discover and develop new GLP-1-based therapies for metabolic and chronic diseases, leveraging Flagship’s bioplatform companies.
  • Q4 2024: Eli Lilly announces $2 billion expansion of Indiana manufacturing site for GLP-1 drugs Eli Lilly committed $2 billion to expand its Indiana manufacturing campus, increasing capacity for its GLP-1 analogue drugs to address persistent supply shortages.
  • Q1 2025: Novo Nordisk completes acquisition of Catalent for $16.5 billion to secure GLP-1 drug supply chain Novo Nordisk finalized its $16.5 billion acquisition of contract manufacturer Catalent, aiming to strengthen its supply chain and manufacturing capabilities for GLP-1-based medicines.
  • Q1 2025: Eli Lilly acquires Synthekine for $1.2 billion to expand GLP-1 and metabolic disease pipeline Eli Lilly announced the acquisition of Synthekine, a biotech specializing in cytokine therapeutics, to enhance its pipeline of GLP-1 and related metabolic disease treatments.
  • Q2 2025: Novo Nordisk opens new R&D center in Boston focused on next-generation GLP-1 analogues Novo Nordisk inaugurated a new research and development center in Boston, dedicated to advancing next-generation GLP-1 analogues and related metabolic disease therapies.

GLP 1 Analogue Market Segmentation Insights

GLP 1 Analogue Market Formulation Outlook

  • Injectable
  • Oral
  • Nasal
  • Transdermal

GLP 1 Analogue Market Dosage Strength Outlook

  • 1 mg
  • 1-5 mg
  • 5 mg

GLP 1 Analogue Market Target Population Outlook

  • Type 1 Diabetes
  • Type 2 Diabetes

GLP 1 Analogue Market Distribution Channel Outlook

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

GLP 1 Analogue Market Regional Outlook

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa
Report Attribute/Metric Details
Market Size 2024   26.34 (USD Billion)
Market Size 2025   29.27 (USD Billion)
Market Size 2034   75.62 (USD Billion)
Compound Annual Growth Rate (CAGR)   11.12 % (2025 - 2034)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2024
Market Forecast Period 2025 - 2034
Historical Data 2020 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Emisphere Technologies, Intarcia Therapeutics, Lexicon Pharmaceuticals, AstraZeneca, PhaseBio Pharmaceuticals, Incretins, Xeris Pharmaceuticals, Eli Lilly and Company, Sanofi, Novo Nordisk, Merck Co., Inc., Zosano Pharma, Zealand Pharma, Boehringer Ingelheim, Rhythm Pharmaceuticals
Segments Covered Formulation, Dosage Strength, Target Population, Distribution Channel, Regional
Key Market Opportunities 1 Rising prevalence of type 2 diabetes 2 Growing demand for injectable drugs 3 Increasing awareness of GLP1 analogues 4 Technological advancements in drug delivery 5 Government initiatives to reduce diabetes burden
Key Market Dynamics Increasing diabetes prevalence Technological advancements Rising obesity rates Government initiatives Growing awareness of GLP1 analogs
Countries Covered North America, Europe, APAC, South America, MEA


Frequently Asked Questions (FAQ):

The GLP 1 Analogue Market is expected to reach USD 75.62 billion by 2034, growing at a CAGR of 11.1% from 2025 to 2034.

North America is expected to dominate the GLP 1 Analogue Market throughout the forecast period.

The increasing prevalence of diabetes and obesity, the rising demand for minimally invasive procedures, and the growing adoption of GLP-1 analogs in the treatment of type 2 diabetes are the key factors driving the growth of the GLP 1 Analogue Market.

The major applications of GLP 1 Analogues include the treatment of type 2 diabetes, obesity, and other metabolic disorders.

The key competitors in the GLP 1 Analogue Market include Novo Nordisk, Sanofi, Eli Lilly and Company, and AstraZeneca.

The GLP 1 Analogue Market is expected to grow at a CAGR of 11.12% from 2025to 2034.

Comments

Leading companies partner with us for data-driven Insights.

clients

Kindly complete the form below to receive a free sample of this Report

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
report-img